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EMP2 regulates angiogenesis in endometrial cancer cells through
induction of VEGF
LK Gordon1, M Kiyohara2, M Fu2, J Braun2,3, P Dhawan4, A Chan1,2, L Goodglick2,3 and M Wadehra2,3
Understanding tumor-induced angiogenesis is a challenging problem with important consequences for the diagnosis and
treatment of cancer. In this study, we define a novel function for epithelial membrane protein-2 (EMP2) in the control of
angiogenesis. EMP2 functions as an oncogene in endometrial cancer, and its expression has been linked to decreased survival.
Using endometrial cancer xenografts, modulation of EMP2 expression resulted in profound changes to the tumor microvasculature.
Under hypoxic conditions, upregulation of EMP2 promoted vascular endothelial growth factors (VEGF) expression through a HIF-1a-
dependent pathway and resulted in successful capillary-like tube formation. In contrast, reduction of EMP2 correlated with reduced
HIF-1a and VEGF expression with the net consequence of poorly vascularized tumors in vivo. We have previously shown that
targeting of EMP2 using diabodies in endometrial cancer resulted in a reduction of tumor load, and since then we have constructed
a fully human EMP2 IgG1. Treatment of endometrial cancer cells with EMP2-IgG1 reduced tumor load with a significant
improvement in survival. These results support the role of EMP2 in the control of the tumor microenvironment and confirm the
cytotoxic effects observed by EMP2 treatment in vivo.
Oncogene (2013) 32, 5369–5376; doi:10.1038/onc.2012.622; published online 21 January 2013
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INTRODUCTION
Sprouting angiogenesis—the process by which new blood vessels
grow from existing ones—is a ubiquitous phenomenon in health
and disease. It has a pivotal role in diverse processes from embryo
development to wound healing to tumor growth.1 Regarding
tumor angiogenesis, it has been shown that solid tumor growth
depends on successful neovascularization and several factors, the
most notable being vascular endothelial growth factors (VEGFs),
have been shown to promote tumor angiogenesis. VEGFs were
first described as a potent vascular permeability factor (VPF)
secreted by tumor cells that stimulate a rapid and reversible
increase in microvascular permeability without mast cell
degranulation or endothelial cell damage.2 Its importance in
tumor biology has led to the development of several drugs, the
most notable being the recently FDA-approved bevacizumab
(Avastin; Genentech, San Francisco, CA, USA)—a humanized anti-
VEGF antibody, as anticancer agents.3,4
VEGF polypeptides belong to the PDGF family of growth factors,
and are perhaps the most important players that regulate vessel
formation.3 VEGFs are encoded by a family of genes that includes
VEGF-A, -B, -C, -D and placental growth factor.5 They are dimeric
cysteine-linked secreted glycoproteins with a molecular weight of
B40 kDa. Produced in response to hypoxia, specific growth and
differentiation factors, and by oncogenes, VEGFs are produced by
many cell types, including tumor cells.5,6 In tumors, VEGF-A
appears to be most potent angiogenic of the vascular growth
factors,7 and its secretion has been shown to be critical for tumor
growth.3,7 Thus, understanding the mechanisms that control
angiogenesis, and in particular that control VEGF-A expression,
are of paramount importance in tumor biology.
Epithelial membrane protein-2 (EMP2) is a tetraspan protein of
the GAS-3/PMP22 family. Concordant with the role of tetraspans,
EMP2 is thought to curate molecules on the plasma membrane to
regulate the activity of specific signaling complexes. EMP2
coordinates the activity of select integrin isoforms, coalescing in
the activation of FAK and Src.8–10 Recently, EMP2 has also been
revealed as a novel oncogene upregulated in a number of tumors
including endometrial,11 ovarian12 and gliomas.13 Upregulation of
EMP2 expression has been associated with tumor progression,
invasion and poor patient prognosis.11,14
To date, the mechanism of how changes in EMP2 levels affect
the tumor microenvironment has not been evaluated. Using a
model for endometrial cancer, we determined that an important
function of EMP2 is as a regulator of angiogenesis. We
demonstrate that increased EMP2 promotes endothelial cell tube
formation through increased VEGF-A expression. Therapeutic
targeting of EMP2 using monoclonal antibodies reduces tumor
vasculature, identifying a novel mechanism of reducing tumor
load through indirect control of VEGF-A.
RESULTS
EMP2 IgG1 improves endometrial cancer survival
We have previously shown that anti-EMP2 diabodies reduce tumor
load in HEC1A xenografts.15 Since this original study, a
recombinant EMP2 IgG1 antibody has been designed and
shown to be therapeutically beneficial in mouse models of
breast cancer (Fu and Wadehra, submitted). To determine the
efficacy of EMP2 IgG1 for endometrial cancer, subcutaneous
xenografts using the HEC1A/EMP2 cell line were created. Systemic
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weekly injections of EMP2 IgG1 reduced tumor load compared to
control IgG (Figure 1a). This reduction in tumor load translated
into a significant increase in survival for mice treated with EMP2
IgG1 (Figure 1b; P¼ 0.02). Even after 84 days, surviving mice
showed no measurable change in tumor size. Upon histologic
examination, central necrosis was prominent in the tumors after
anti-EMP2 antibody treatment compared with the control
(Figure 1c). Although this can be attributed partially to higher
interstitial pressure and poorer blood flow at the center of
tumors,16,17 significantly less necrosis was visible in tumors with
control IgG antibodies treatment. To analyze these alterations in
tumor vasculature, immunostaining for vasculature was
performed using Lycopersicon esculentum lectin on surviving
clusters of tumor cells. Lectin immunostaining studies confirmed
the marked loss of vessels during anti-EMP2 treatment in areas of
viable tumor (1D).
To further examine whether the reductions in tumor vascularity
from EMP2 treatment were due to vessel regression or reduced
angiogenesis, tumors were stained with Masson’s trichrome to
detect the presence of collagen sleeves18,19 in necrotic areas
(Figure 1e). All treatment groups had scattered fragments of
basement membrane (Figure 1e, arrowheads), but empty base-
ment membrane sleeves were more abundant in areas of necrosis
after the anti-EMP2 antibody than control treatments. This
suggests that blockade of EMP2 is a novel mechanism to reduce
tumor neovascularization.
Tumor-associated vasculature
Recent studies have shown that EMP2 expression is upregulated
in endometrial tumors and that its expression alters tumor cell
development.11,14 Studies have also shown that modulation of
EMP2 does not significantly alter tumor cell proliferation.9
Therefore, we postulated that it may be an important regulator
of the tumor cell microenvironment. To test this idea, tumors were
created from endometrial cancer cells that overexpressed EMP2
(HEC1A/EMP2), expressed a vector control (HEC1A/V) or expressed
a ribozyme to reduce its levels (HEC1A/RIBO). Masson’s trichrome
staining of xenografts suggested that EMP2 expression altered
tumor vasculature (Figure 2a). HEC1A/EMP2 tumors were highly
vascularized, whereas tumors with reduced EMP2 (HEC1A/RIBO)
levels formed small tumors with poor vasculature and large areas
of necrosis.
To confirm that EMP2 levels correlated with increased numbers
of blood vessels, tumors were stained with L. esculentum lectin,
which binds uniformly to the luminal surface of the endothe-
lium,20 and DAPI. HEC1A/EMP2 tumors showed increased tumor-
associated vasculature compared with the HEC1A/V tumors.
Similar staining of HEC1A/RIBO tumors showed poor tumor
vasculature with some background staining in the areas of
necrosis (Figure 2b). Xenografts were also stained with CD34
antibodies (Figure 2c). Concordantly, quantitation of staining
revealed a significant correlation between EMP2 expression and
CD34þ cells (Figure 2d).
EMP2 expression promotes endothelial cell tube formation
We used several approaches to investigate whether and how
EMP2 could regulate the behavior of endothelial cells. Initially, the
chemotactic response of human umbilical vein endothelial cells
(HUVECs) to supernatants from EMP2-modified cell lines was
tested using Boyden chambers. Conditioned media was collected
from cells grown under hypoxic conditions for up to 24 h.
Conditioned media from cells that overexpressed EMP2 signifi-
cantly enhanced directional migration compared to control cells
(P¼ 0.04; Figure 3a). Reduction in EMP2 expression further
reduced cell migration by two-fold over control cells (P¼ 0.03).
To confirm that EMP2 expression altered endothelial cell
migration, a ‘scratch’ test was performed on a confluent
monolayer of HUVEC cells. Concordant with the previous results,
an EMP2 dose-dependent response was also observed using
conditional medium from hypoxic HEC1A/EMP2, HEC1A/V or
HEC1A/RIBO cells (Figure 3b). No statistically significant differences
were observed from conditioned media collected from normoxic
cells (data not shown).
To determine whether EMP2 altered the functional behavior of
endothelial cells, HUVEC cells were placed on a basement
membrane matrix to induce capillary-like tube formation.21 Cells
were incubated in hypoxic cultured supernatants from HEC1A/
EMP2, HEC1A/V and HEC1A/RIBO (Figure 3c). An EMP2-dependent
response was observed in capillary-like tube formation, as HEC1A/
EMP2 induced more tube formation and tubes with a greater
diameter than HEC1A/V (Figures 3d and e). Reduction in EMP2
expression in HEC1A cells further reduced the number of tubes
formed compared with HEC1A/V, suggesting that EMP2 expres-
sion is necessary for endometrial tumor angiogenesis. This effect
was also observed when EMP2 levels were reduced using shRNA,
and although a similar trend in capillary-like tube formation was
observed from normoxic cultured supernatants between HEC1A/
EMP2 and HEC1A/V, these results were not statistically significant
(data not shown). No significant difference in HUVEC cell
proliferation was observed within the experimental window (data
not shown).
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Figure 1. EMP2 IgG1 treatment reduces tumor load. (a) HEC1A/EMP2
cells were injected subcutaneously into nude BALB/c female mice.
When tumors reached 4mm2, control of EMP2 IgG1 antibodies were
systemically injected at 10mg/kg. Mice were treated weekly, and
tumor volume was monitored using calipers. N¼ 6. *Po0.05. (b)
Kaplan–Meier survival analysis of the outcome of athymic mice
treated with anti-EMP2 IgG1 or a control antibody. N¼ 6; P¼ 0.02. (c)
Treated tumors were harvested and fixed. Tumors were visualized
using hematoxylin and eosin. Magnification:  4. (d) Neovascular-
ization of HEC1A/EMP2 tumors treated with EMP2 IgG1 or control
antibodies was visualized using L. esculentum lectin and DAPI in
surviving tumor clusters. (e) Masson’s trichrome stain was used to
identify basement membrane sleeves in central areas of the tumor.
N¼ 3, with a representative image shown. Magnification:  10.
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The reduction in vessel formation in HEC1A/RIBO and HEC1A/
sh911 suggested that EMP2 in part regulated the tumor
microenvironment via new blood vessel formation. In order to
link anti-EMP2 treatment with changes in neovascularization, we
initially treated HEC1A/EMP2 cells for 12–15 h under hypoxic
conditions with anti-EMP2 IgG1 or control antibodies to determine
their effect on capillary-like HUVEC tube formation, as no cellular
toxicity was visible at this early time point. EMP2 IgG1 treatment
was sufficient to reduce HUVEC tube formation in vitro in a dose-
dependent manner (Figure 3f).
To determine if the effects of EMP2 on endothelial cells are cell
type specific, similar experiments were performed on primary
human aortic endothelial cells (HAEC). Using supernatant from
hypoxic HEC1A/EMP2, HEC1A/V or HEC1A/RIBO as a chemoat-
tractant, Boyden chamber assays were performed on HAEC.
Similar to results using HUVEC cultures, tumor expression of EMP2
promoted HAEC invasion (Figure 4a). These combined results
suggest that EMP2 upregulation leads to an increase in pro-
angiogenic events. Several cellular and molecular changes have been
shown to promote tumor angiogenesis,22 with the most potent
inducer being VEGF.23 In order to determine if VEGF contributed to
HAEC invasion, tumor cell supernatants were incubated with
bevacizumab, a monoclonal antibody to VEGF. Treatment with
bevacizumab reduced HAEC migration to control levels, suggesting
that EMP2 may regulate VEGF expression (Figure 4a).
EMP2 regulates VEGF expression
In order to determine if EMP2 expression altered VEGF expression
and secretion, cells were grown in normoxia or placed in a hypoxic
chamber for 24 h. VEGF expression was below detection under
normoxic conditions. However, when cells were placed in hypoxia,
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Figure 2. EMP2 expression increases tumor vasculature. (a) 1 106 HEC1A/EMP2, HEC1A/V or HEC1A/RIBO cells were injected subcutaneously
into Balb/c nude mice. After 30 days, tumors were harvested, fixed and stained with Masson’s trichrome. N¼ 6. (b) Tumors were stained using
L. esculentum lectin and DAPI. (c) Tumors were stained for CD34 expression. In all images, arrows highlight tumor vasculature. Magnification:
 20. Scale bar¼ 100 mm. (d) The numbers of CD34þ blood vessels in six high-power fields ( 200) from at least two independent tumors
were counted and averaged. Bars, mean±s.e.
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EMP2 expression directly correlated with total VEGF protein levels
(Figure 4b) as well as with secreted VEGF (Figure 4c). In contrast,
reduction of EMP2 resulted in undetectable levels of VEGF by
western blot and low levels of secreted protein. To confirm these
results, semi-quantitative RT-PCR was performed on hypoxic
HEC1A/EMP2, HEC1A/V and HEC1A/RIBO cells. VEGF-A exists as
multiple isoforms, which are generically referred to as VEGFxxx
and result from the pre-mRNA alternative splicing of eight
exons.24 Alternative splicing of VEGF-A was initially shown to
generate four different isoforms with 121, 165, 189 and 206 amino
acids (VEGF121, VEGF165, VEGF189, VEGF206, respectively25).
EMP2 levels directly increased the mRNA expression of several
VEGF isoforms (VEGF165 and VEGF121), whereas a reduction in
EMP2 produced reduced VEGF expression (Figure 4d). Low levels
of VEGF189 mRNA was observed in HEC1A/EMP2 cells, and no
expression of VEGF206 was detected in any of the cell lines.
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Figure 3. EMP2 promotes angiogenesis. (a) Chemotactic effects on the migration of HUVECs were measured using a standard Boyden
chamber assay. HUVEC cells were stimulated to migrate in response to cultured media from hypoxic HEC1A/EMP2, HEC1A/V or HEC1A/RIBO
cells. Experiments were repeated three times with data representing the mean±s.e. (b) HUVEC cells’ migration was measured using a ‘scratch’
wound healing assay. Endothelial cells were cultured in hypoxic tumor cell supernatant, and wound closure was measured using microscopy.
(c) HUVEC cells were plated on low growth factor matrigel in the presence of cultured media from hypoxic HEC1A/EMP2, HEC1A/V or HEC1A/
RIBO cells. The experiment was repeated at least three times, and a representative image is shown. Capillary-like tube formation was
quantitated by measuring the number of tubes (d), as well as the tube diameter (e). The data in the graph is the mean±s.e.m. of the three
fields using three independent experiments. (f ) An equivalent number of HEC1A/EMP2 endometrial tumor cells were treated for 12 h under
hypoxic conditions with varying concentrations of EMP2 IgG1 or control IgG. Supernatants were collected and added to HUVEC plated on low
growth factor matrigel. Capillary tube formation was measured using phase contrast microscopy after 12–24 h. The experiment was repeated
three times, with the data presented as the mean±s.e., *Po0.05.
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In the previous experiments, we demonstrated that down-
regulation of EMP2 in the tumor cell reduced capillary formation,
and the motility of endothelial cells using coculture assays. This
may be the result of reduced VEGF secretion by these cells or due
to the expression of anti-angiogenic agents. To address this
question, varying amounts of VEGF were added to the super-
natants from vehicle control or cells with reduced EMP2 levels
(HEC1A/RIBO or HEC1A/sh911). Exogenous VEGF was sufficient to
induce HUVEC cell tube formation (Figure 4e), suggesting that the
absence of VEGF contributed to the lack of tube formation.
EMP2 promotes HIF-1a expression through a Src-mediated
pathway
Several oncogenic as well as growth factor-driven pathways have
been shown to regulate VEGF expression. As hypoxic conditions
have been shown to trigger many oncogenic signaling
pathways,26 we initially investigated if the levels of EMP2 were
sufficient to alter the expression of hypoxia-induced transcription
factors (HIF), specifically HIF-1a and HIF-2a. In all EMP2 HEC1A
variants, no expression of HIF-2a was observed (data not shown).
However, the expression of HIF-1a correlated with EMP2
expression. The highest levels of HIF-1a directly correlated with
the highest concentration of EMP2 expression under hypoxic
conditions (Figure 5a). Reciprocally, HEC1A/RIBO cells produced
below detection levels of HIF-1a under the same conditions. To
confirm that lower levels of EMP2 reduce HIF-1a expression,
shRNA constructs were generated to express a vehicle control or
reduce EMP2 expression (Figure 5a, right). Similar to the ribozyme,
HEC1A/sh911 showed reduced HIF-1a expression compared to the
vehicle control (HEC1A/shCtrl). To quantitate the difference in
HIF-1a expression between the cell lines, blot intensities were
analyzed using Image J. HEC1A/EMP2 cells significantly induced
HIF-1a expression compared to HEC1A/V cells (Figure 5b;
P¼ 0.0008). Reduction in EMP2 in HEC1A/RIBO, also showed a
significant reduction in HIF-1a expression (P¼ 0.02).
HIF proteins have a number of important roles in cellular
physiology that include the regulation of angiogenesis as well as
metabolism.26,27 To determine if the regulation of HIF-1a
expression by EMP2 is restricted to VEGF, proteins involved with
glycolysis were examined (Figure 5c). EMP2 expression directly
correlated with glucose transporter-1 (GLUT1) expression, and
significant differences were observed between HEC1A/EMP2 and
HEC1A/sh911 (P¼ 0.04). Whereas high EMP2 also appeared to
slightly increase the expression of lactate dehydrogenase A, no
significant differences were observed between the cell lines
(Figure 5c).
We next focused on understanding the mechanism by which
EMP2 regulated HIF-1a expression. As EMP2 has been shown to
promote integrin-mediated FAK and Src activation,9,28 the
contribution of FAK/Src signaling to HIF-1a expression was
determined. Using common inhibitors of AKT, PI3-kinase, EGFR
and Src tyrosine kinases, HEC1A/EMP2 cells were treated with
these agents while in a hypoxic chamber. As shown in Figure 5b,
EMP2-induced overexpression of HIF-1a was reversed using Src
inhibitors PP2 and dasatinib, respectively. Both erlotinib and
Ly294002, a PI3-kinase inhibitor, also produced a similar effect,
suggesting an overlap in signaling with EMP2. In contrast, AKTi did
not alter HIF-1a expression in these cells (Figure 5d).
To validate the effects of FAK signaling on HIF-1a expression,
HEC1A/EMP2 and HEC1A/V cells were transiently transfected with
scrambled or FAK siRNA (Figure 5e). After 24 h in a hypoxic
chamber, HIF-1a expression was determined. Reduction in FAK
expression significantly diminished HIF-1a expression in both cell
lines (Figure 5e, right). A 68±3% reduction in FAK expression
decreased HIF-1a expression by 48±3% in HEC1A/EMP2 cells. A
similar reduction was observed in HEC1A/V cells where decreasing
FAK expression by 51±5% produced an 82±8% drop in HIF-1a
expression.
DISCUSSION
EMP2 is a novel oncogene upregulated in a number of cancers in
women. In endometrial cancer, for example, EMP2 expression
promotes endometrial cancer growth in vivo,9 and to date, it is the
only biomarker identified to predict endometrial cancer prognosis
and survival.11,14 Given its expression profile and importance in
disease pathogenesis, we previously generated a recombinant
antibody fragment (diabody) to EMP2, and have shown that it
induces necrosis in vivo.15 Since then, we have generated an EMP2
IgG1 with similar in vitro and in vivo properties (Fu and Wadehra,
submitted), and have started to characterize its mechanism of
action in vitro and in vivo.
Using endometrial cancer cells, EMP2 IgG1 treatment signifi-
cantly reduced tumor load with a net improvement in survival.
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Figure 4. EMP2 regulates VEGF expression. (a) A Boyden chamber
assay was used to determine HAEC response to cultured hypoxic
tumor cell supernatants. In some experiments, the anti-VEGF
antibody bevacizumab, which binds soluble VEGF was added at
10mg/ml to the cultured supernatant. (b) The expression of total
VEGF was measured using western blot analysis on cells placed in a
0.5% hypoxic chamber for 24 h. EMP2 expression was verified in cell
lines, where its expression was either upregulated as an EMP2-GFP
fusion protein (45 kDa) or reduced using an EMP2-specific ribozyme;
endogenous EMP2 is 18 kDa. b-actin was used as the loading
control. (c) Secreted VEGF from hypoxic cells was measured using an
ELISA. (d) Semi-quantitative expression of VEGFxxx mRNA was
determined using RT-PCR on hypoxic tumor cells. The experiment
was repeated three times with similar results, and a representative
blot is shown. GAPDH expression serves as a loading control. (e)
Exogenous VEGF was added to cultured media obtained from
hypoxic HEC1A/RIBO or HEC1A/sh911 cells at 20 or 50 ng/ml.
Capillary-like tube formation was measured using phase contrast
microscopy after 12–24 h. The experiment was repeated three times,
with the data presented as the mean±s.e.
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Within tumors, significant necrosis was observed. To understand
its mechanism of action, we generated cells with reduced EMP2
expression using ribozymes or specific shRNA constructs, which
revealed a similar histology. In particular, severe necrosis was
observed in tumors with reduced EMP2. Although we had
previously observed increased cell death in vitro after exposure
to antibodies that recognize EMP2, the necrotic response and the
studies reported in this paper link EMP2 with control of VEGF
expression through HIF-1a. Notably, HEC1A cells that were
genetically modified for EMP2 expression showed a positive
correlation between EMP2 levels and tumor vascularity. Cell
supernatants from cells that were genetically modified for EMP2
expression showed a positive correlation between EMP2 levels,
and endothelial cell migration and tube formation of two
independent endothelial types under hypoxic conditions. Levels
of VEGF and HIF-1a were concordant also with expression levels of
EMP2, and blockade of EMP2 using an anti-EMP2 antibody
showed a dose-dependent decrease in vascularization.
Whereas additional investigations will be needed to identify
how EMP2 controls HIF-1a expression, its effects do not appear to
be limited to angiogenesis. As HIF-1 also regulates metabolism,26
the significant alteration in GLUT1 expression suggests that EMP2
upregulation may have an adaptive role in promoting and
establishing endometrial cancer tumorigenesis.Whereas it is
known that several oncogenes stimulate angiogenesis,29 all of
the studies presented here point to a significant effect on HIF-1a
and VEGF through control of EMP2 expression, and suggest the
mechanism for the clinical association of high EMP2 expression
with aggressive, more advanced tumors.12,14 Our results also
suggest that EMP2 activates HIF-1a in a hypoxic environment
through a FAK-Src-dependent mechanism. Although a similar
trend in HUVEC migration and wound closure was observed under
normoxic conditions, the differences were not statistically
significant (data not shown). Under hypoxic conditions, the
control of angiogenesis by EMP2 appears to be independent of
AKT activation, suggesting that EMP2 and AKT regulate separate
pathways. This is consistent with published reports that AKT
signaling is neither required for HIF-1a expression nor stabilization
under hypoxic conditions.30 Although AKT inhibitors did not
suppress EMP2 mediated HIF-1a activation, erlotinib and
Ly294002, the phosphatidylinositol 3-kinase (PI3K) inhibitor,
were sufficient to inhibit its expression. This is not unexpected
as EGFR neutralizing antibodies have been shown to have potent
antitumor cytotoxic-like effects in vivo (where angiogenesis is
required) but not in vitro (where it is not).23 This would also
suggest that in endometrial cancer cells, similar to what has been
observed in other tumor models, EGFR stimulates HIF-1a
activation via a PI3K-mediated but AKT independent
manner.31,32 Is there overlap between EMP2 and EGFR signaling?
We hypothesize that there is some overlap. Previous studies have
shown that EMP2 promotes integrin expression and
activation.33,34 As both integrins and EGFR can signal through
MAP kinase activation, we predict this may be a common thread
between the two pathways.31,35
The data presented here suggest that anti-EMP2 therapy in the
disease has a combination of effects (direct toxicity and indirect
regulation of VEGF) that supports its therapeutic potential. This is
particularly important, given that the promise of anti-angiogenic
agents has been incomplete.36 Initial clinical successes, prolonged
overall and progression-free survival, using anti-VEGF antibody
therapy in colorectal cancer prompted more widespread clinical
use of these agents. However, these promising results were not
replicated in multiple tumor types including metastatic breast
cancer, resulting in withdrawal of FDA approval for its use in this
tumor type. Indeed, some tumors escape VEGF inhibition through
both hypoxia-dependent and hypoxia-independent manners. In
addition, VEGF blockade may lead to proinflammatory molecules
that might enhance tumor progression.37 Could a similar effect be
observed with longer anti-EMP2 treatment? Although our results
are promising, additional investigations are required to further to
define the long-term consequences of anti-EMP2 treatment.
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Figure 5. EMP2 regulates VEGF through FAK-Src mediated control of
HIF-1a. (a) EMP2 expression was downregulated using either a
ribozyme (HEC1A/RIBO) or shRNA lentiviral constructs (HEC1A/
sh911). Appropriate vehicle control cells were included. To
determine the mechanism for VEGF regulation, HIF-1a and PPARg
expression were determined using western blot analysis on hypoxic
cells. b-actin expression serve as the loading control. (b) Quantita-
tion of HIF-1a expression in HEC1A/EMP2, HEC1A/V and HEC1A/
RIBO relative to b-actin from three independent experiments. The
data represents the mean±s.e. (c) To determine if other HIF-1a
regulated proteins were altered by EMP2 levels, hypoxic lysates were
probed for GLUT1 and lactate dehydrogenase A expression. Below,
quantitation of GLUT1 expression from three independent blots.
*P¼ 0.04. (d) HEC1A/EMP2 cells were incubated with the PP2, PP3,
Dasatinib, Erlotinib, Ly294002, AKTi VIII, a DMSO vehicle control or a
media control for 24 h in a 0.5% hypoxic chamber. Cells were probed
for the protein expression of HIF-1a, p-FAK, p-SRC, p-AKT and
b-actin. (e) HEC1A/EMP2 or HEC1A/V cells were transiently trans-
fected with FAK siRNA or a scrambled control. Lysates were created
from cells placed in a hypoxic chamber for 24 h and analyzed using
SDS-PAGE/western blot analysis. Blots were probed for HIF-1a, total
FAK and b-actin levels. Right, quantitation of HIF-1a levels relative to
b-actin following transfection of cells with a FAK or scrambled siRNA.
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MATERIALS AND METHODS
Cell lines
The human endometrial adenocarcinoma cell line HEC1A (HTB112, ATCC,
Manassas, VA, USA) was cultured in McCoys media supplemented with 10%
fetal calf serum at 37 1C in a humidified 5% CO2 incubator. Cell lines were
used within 2 months after resuscitation of frozen aliquots, and were
authenticated based on viability, recovery, growth, morphology and
isoenzymology by the supplier. Stably transfected HEC1A cells containing
a human EMP2-GFP fusion protein, control GFP or EMP2-specific ribozyme
have been previously described.33,38 Stably infected HEC1A cells containing
a non-targeting shRNA control (HEC1A/shCtrl) or EMP2-specific shRNA
(HEC1A/sh911) (911; TRCN0000322911) in pLKO.1-puro were generated as
per manufacturer’s instructions (Sigma-Aldrich, St Louis, MO, USA).
Human umbilical vein endothelial cells (HUVEC) from passage 2 were
purchased from BD Biosciences (San Diego, CA, USA), and used between
passages 3 and 7 for all experiments. Primary HAECs (gift from Dr J Berliner,
UCLA) were also utilized. All endothelial cells were grown in complete
MCDB-131 complete media (VEC Technologies, Renesselaer, NY, USA).
Preparation of xenografts
Ethical treatment of animals statement: This study was carried out in strict
accordance with the recommendations in the Guide for the Care and Use
of Laboratory Animals of the National Institutes of Health. The protocol was
approved by the Animal Research Committee at the University of
California, Los Angeles CA, USA. All efforts were made to minimize animal
suffering.
Four- to six-week-old nude BALB/c female mice were obtained from
Charles River Laboratories (Wilmington, MA, USA) and maintained at the
University of California, Los Angeles, CA, USA. Animals were inoculated
subcutaneously with 1 106 HEC1A/EMP2, HEC1A/V or HEC1A/RIBO cells
into the right and left shoulder flanks, respectively. Tumors were measured
using calipers, and the volume calculated with the formula: length
width2/2. Six mice were used per group. At day 30, tumors were excised,
fixed in formalin, and then processed for hematoxylin and eosin staining
by the Tissue Procurement Laboratory at UCLA or by Masson’s trichrome
stain (Dako, Carpinteria, CA, USA).
In some experiments, 1 106 HEC1A/EMP2 cells were suspended in 5%
matrigel (BD Biosciences, Franklin Lakes, NJ, USA) and injected subcuta-
neously into the shoulder of female athymic mice. When tumors
approached 4mm2, systemic treatments with 10mg/kg dose of anti-
EMP2 IgG1 or control IgG (Sigma-Aldrich) were administered weekly via an
intraperitoneal route. Tumor size was monitored, and mice euthanized
once tumors approached 1.5 cm in diameter, mice appeared moribund or
showed a 10% reduction in weight, or tumors became ulcerated. Tumors
were isolated, fixed and processed for hematoxylin and eosin staining as
previously described.14
Cytochemistry and immunohistochemistry
Samples were analyzed to quantitate and identify tumor vasculature.
Masson’s trichrome staining was performed according to the manufac-
turer’s instructions (Dako). Samples were deparaffinized and dehydrated in
alcohol. In some experiments, after blocking in 1% normal goat serum,
samples were incubated with 1:50 dilution of FITC-labeled L. esculentum
lectin (1mg/ml in 0.9% NaCl; Vector Laboratories, Burlingame, CA, USA).
Samples were then counterstained with DAPI and mounted. To quantitate
CD34 expression, samples were deparaffinized and then incubated at 95 1C
for 20min in 0.1 M citrate, pH 6.0. Rat anti-CD34 (Abcam, Cambridge, MA,
USA) was used at a dilution of 1:25 as previously described39, followed by
visualization using the Vector ABC kit (Vector Laboratories, Burlingame, CA,
USA) according to the manufacturer’s instructions. The numbers of CD34-
positive blood vessels in six high-power fields ( 200) were counted and
averaged.
Capillary tube formation
Capillary-like tube formation was performed as previously described.40
Briefly, coverslips were coated with reduced growth factor basement
membrane (Geltrex; Invitrogen, Carlsbad, CA, USA) and incubated at 37 1C
for 30min to promote jelling. 5 105 HUVECs were resuspended in
cultured media from HEC1A/EMP2, HEC1A/V or HEC1A/RIBO cells.
Conditioned media was typically prepared as follows: cells were grown
in a bag to mimic hypoxic conditions for up to 72 h or placed in a 0.5%
hypoxic chamber (BioSpherix, Lacona, NY, USA) for up to 24 h. The cultured
media was then collected and centrifuged to remove cell debris. In some
experiments, HEC1A or HEC1A/EMP2 cells were treated with 100mg/ml of
the full-length EMP2 IgG1 for 24 h under hypoxic conditions for 12–15h. In
other experiments, recombinant human VEGF (Sigma-Aldrich) was used as
an inducer of capillary tube formation from 0–50 ng/ml on HUVEC cells.
After 18 h, cells were stained with calcein AM and analyzed using an
Olympus BX51 light microscope. Tubes were counted using a 10
objective connected to a DP72 digital camera. Three random fields were
measured at each culture condition. Each experiment was repeated at least
three times.
Migration assays
HUVEC and HAEC migration assays were conducted in Boyden chambers
as previously reported (2). Conditioned media was prepared as described
above. In some experiments, cultured supernatants from tumor cells were
treated with bevacizumab (Genentech BioOncology, South San Francisco,
CA, USA). Bevacizumab was obtained from the pharmacy at University of
California, Davis, CA, USA. Each condition was assayed in triplicate wells.
‘Scratch’ wound closure assays were performed by creating a confluent
monolayer of HUVEC cells. Using the tip of a Pasteur pipet, a scratch was
created. Conditioned media from HEC1A/EMP2, HEC1A/V or HEC1A/RIBO
cells were added to the wells. Three random measurements for each of the
three wounds were measured for each test condition. The experiment was
repeated three times.
Semi-quantitative RT-PCR
For RT-PCR analysis, total cellular RNAs were isolated using RNeasy mini kit
(Qiagen, Valencia, CA, USA). In all conditions, 1 mg of total RNA was
reversed transcribed using oligo(dT) primers and Moloney murine
leukemia virus reverse transcriptase (Invitrogen). For VEGF amplification
including all four splice variants, the PCR conditions and primers were
utilized as previously described.41 Amplification of a GAPDH cDNA
fragment was performed in a separate PCR reaction as described.42 PCR
products were run on a 2% agarose gel and were visualized by ethidium
bromide staining.
FAK siRNA
In some experiments, cells were transiently transfected with FAK siRNA or a
scrambled control as previously described.8 Briefly, HEC1A/EMP2 or
HEC1A/V cells were transiently transfected with 75 pmol FAK siRNA
(L-003164-00, ThermoScientific, Lafayette, CO, USA) or a scrambled
control (D-001206-13-05, ThermoScientific). After 6 h, cells were placed in
a 0.5% hypoxic chamber for 24 h and then processed for western blot
analysis as detailed below.
Western blot analysis
Cells were lysed in Laemmli buffer. Proteins were separated by SDS-PAGE,
transferred to a nitrocellulose membrane (GE Healthcare Biosciences,
Piscataway, NJ, USA), and stained with Ponceau S (Sigma-Aldrich) to
determine transfer efficiency. Membranes were blocked with 10% low-fat
milk in PBS containing 0.1% Tween 20 and probed with EMP2 antisera
(1:1000), anti-VEGF (Santa Cruz Biotech, Santa Cruz, CA, USA), anti-HIF-1a
(1:800; BD Biosciences), anti-PPAR-g (Santa Cruz Biotech), anti-416 p-Src
(Cell Signaling, Danvers, MA, USA), anti-p-AKT (Cell Signaling), anti-576/577p-
FAK (1:500; BD Biosciences) or b-actin (Sigma-Aldrich). Protein bands were
visualized using a horseradish peroxidase-labeled secondary antibody (BD
Biosciences; Southern Biotechnology Associates, Birmingham, AL, USA)
followed by chemiluminescence (ECL; GE Healthcare Biosciences). Band
intensities were quantified using the NIH program Image J as above. To
account for loading variability b-actin was used to normalize each sample.
At least three independent experiments were performed and, where
indicated, the results were evaluated for statistical significance using a
Student’s t-test (unpaired, one-tail). A level of Po0.05 was considered to be
statistically significant.
In some experiments, inhibitors were added to determine the
contribution of specific pathways to HIF-1a expression. HEC1A/EMP2 cells
were treated with 10 mM of the FAK-Src small molecule inhibitor PP2 or the
small molecule control PP3,8 5 mM of Akt inhibitor VIII (Barnett et al.16
Calbiochem, San Diego, CA, USA), 50mM of the PI3 kinase inhibitor
Ly294002 (Cell Signaling), the EGFR inhibitor Erlotinib (Wang et al.17 10mM,
Genentech) or the Src family tyrosine kinase inhibitor Dasatinib (Lu et al.43
10mM, Bristol-Myers Squibb). Efficacy of the inhibitors was tested at
the manufacturer’s recommended dosage, and potential toxicity was
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measured using trypan-blue exclusion. Samples were harvested and
probed by SDS–PAGE/western blot analysis as above.
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